ASCO 2026 Special — Comprehensive Opening Weekend: Daraxonrasib Doubles Pancreatic OS

Servier drops one-point-five-five billion upfront to carve out Edgewise's muscular dystrophy franchise — total deal value, up to two-point-six-five billion.

Plus Lilly pushes into GLP-2, ASCO reshuffles the oncology pecking order across three tumor types, Skyhawk posts Huntington's data the field has been waiting for, and the White House just pulled six vaccines off the childhood schedule. Loaded Monday.

Welcome to The Pharma Closeout for Monday, June first, twenty twenty-six. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it.

Top story. French pharma Servier is acquiring Edgewise Therapeutics' muscular dystrophy business — up to two-point-six-five billion dollars. One-point-five-five billion upfront, one-point-one billion in additional milestones. The lead asset is sevasemten, currently in a pivotal Becker muscular dystrophy trial and Phase 2 for Duchenne. Edgewise keeps its cardiovascular portfolio and pivots entirely to that focus. Let's bring in Marcus Webb on the deal architecture.

The biology here is fundamentally different from what's come before in dystrophy. Sevasemten is a fast skeletal myosin inhibitor — it doesn't attempt to restore dystrophin. Instead, it dials down the contractile force that tears muscle fibers during normal use. Orthogonal to every exon-skipping and gene therapy approach in this space, and it opens real combination rationale down the line.

The science tracks. But Servier's pedigree is oncology and cardiovascular — rare neuromuscular disease demands specialty commercial infrastructure they've never had to build.

Infrastructure is a solvable problem if the molecule delivers. What's less certain is whether pivotal Becker results translate to Duchenne — different disease severity, different natural history, different regulatory bar. Servier's pricing assumes both indications work. That's a wager, not a foregone conclusion.

And this deal fits a pattern worth naming. Private European pharma is showing up aggressively for rare disease assets and paying pre-data premiums to lock them down. If the Becker readout later this year hits, the milestone math rewards Servier handsomely. If it misses, one-point-five-five billion is a very expensive tuition bill.

The Edgewise deal wasn't the only nine-figure check written today. Lilly licensed sonefpeglutide, a GLP-2 receptor agonist for short bowel syndrome, from Korea's Hanmi Pharmaceutical — seventy-five million upfront, up to one-point-two-six billion total. This stacks on last week's three-point-eight billion in vaccine acquisitions, plus a separate discovery pact with China's Haisco announced alongside it.

GLP-2 agonism promotes intestinal mucosal growth and adaptation — in short bowel, patients who've lost significant small intestine are often tethered to parenteral nutrition indefinitely, sometimes twelve-plus hours a day on an IV line. Takeda's teduglutide defined the category, but the unmet need remains enormous. Lilly sees white space in a niche market with very high per-patient value, and that's classic Lilly calculus.

Staying with Lilly — Kelonia Therapeutics shared in vivo CAR-T data over the weekend that further validates that acquisition thesis. The approach bypasses ex vivo manufacturing entirely, and if the clinical signals hold, it could reshape the cost architecture of cell therapy at scale.

Step back and look at what Lilly has assembled in the past ten days alone — metabolic assets, vaccines, cell therapy platforms. They're not plugging a single pipeline gap. They're buying optionality across platform technologies. That's a fundamentally different strategic posture from filling a hole.

Now, ASCO — where the oncology map is being redrawn in real time. Akeso and Summit's Harmoni-6 delivered a thirty-four percent overall survival improvement for ivonescimab plus chemo in lung cancer, though detailed data are already being picked apart. Revolution Medicines posted pancreatic cancer results analysts are calling unprecedented, pointing toward a paradigm shift in RAS-driven tumors. Pfizer one-upped J&J's Erleada in prostate cancer. And Merck is gearing up a massive Phase 3 program for sac-TMT. Three major tumor types seeing their hierarchies reshuffled simultaneously — portfolio recalibration across large-cap oncology starts this week.

The RevMed pancreatic data deserve the most attention. If those survival curves hold under peer scrutiny, it changes the treatment algorithm in a disease where the five-year survival rate has barely moved in decades. That's the kind of inflection that redirects clinical development programs industry-wide.

Two more pipeline items worth your time. Skyhawk Therapeutics released twelve-month data from its Phase 1/2 trial of SKY-0515 in Huntington's disease. Treated patients showed a positive cUHDRS change of plus zero-point-three-eight from baseline, versus an expected decline of nearly a full point from natural history analyses. The nine-milligram dose achieved sixty-nine percent reduction in mutant huntingtin protein. And Skyhawk's FALCON-HD pivotal study completed enrollment in Australia and New Zealand six months ahead of schedule — a hundred forty-four patients enrolled — with more than a hundred seventy-five patients now across all Huntington's programs.

Stabilization against an expected decline of nearly a full cUHDRS point — in Huntington's, where every disease-modifying attempt has failed to budge that composite score — that's a signal this field has been waiting years to see. If it holds through the pivotal, it could pull capital and clinical attention back into a disease area that many had quietly given up on.

And briefly from the pipeline — new epigenetic editing data showed promise against chronic hepatitis B, offering a distinct angle from the antisense approaches that have led the HBV functional cure conversation. Early-stage, but a technology class to watch closely in liver disease.

Also worth noting on the regulatory side — the FDA approved Shionogi's Xocova, ensitrelvir, for post-exposure prophylaxis of COVID-19. Per the FDA's approval listing, this is the first oral antiviral approved specifically for preventing COVID after exposure — distinct from treatment. Approval came ahead of the June sixteenth PDUFA date, based on the SCORPIO-PEP trial.

That prevention-versus-treatment distinction opens a new competitive lane entirely. Paxlovid treats active infection. Xocova carves out prophylaxis — household contacts, healthcare workers, immunocompromised patients in close-contact settings. Different prescriber base, different patient journey, and a market segment Pfizer hasn't had to share until now.

The bigger regulatory headline involves the childhood vaccine schedule. The Trump administration signed an executive order endorsing the HHS overhaul — removing recommendations for flu, COVID, rotavirus, meningitis, hepatitis A, and hepatitis B vaccines in children. Those shots can still be administered, but only after individual provider consultation.

That touches Merck through RotaTeq, and puts revenue pressure on Sanofi, GSK, and Pfizer across their pediatric portfolios. When a vaccine moves off the recommended schedule, reimbursement follows — and coverage gaps widen.

The procedural shift sounds modest, but in pediatric practice it inverts the clinical default. Physicians go from proactively administering to reactively discussing. Uptake rates will drop — the magnitude is the open question, but the direction is not.

Two more quick items. Replimune is pursuing a third review of its melanoma therapy after what the company called productive FDA discussions. This drug has been rejected twice in what's been one of the more contested agency decisions in recent memory — now getting another look following leadership changes at FDA. Worth watching whether a fresh review team reads the data differently. And separately, new analysis shows the cost of a Priority Review Voucher has roughly doubled over the past three years and looks likely to stay elevated — reshaping the return math for smaller biotechs who bank on PRV monetization as part of their development economics.

Looking ahead — ASCO presentations roll through the week, so expect more oncology data that could reshuffle positioning further. On the June PDUFA calendar, watch Spero Therapeutics for its antibiotic in complicated urinary tract infections, Kiniksa Pharma seeking a manufacturing transfer approval for Arcalyst, and Merck pursuing approval for the WELIREG-KEYTRUDA combination.

The Merck combo is the one to circle. A WELIREG-KEYTRUDA nod would extend Keytruda's combination architecture into renal cell carcinoma and layer additional revenue onto a franchise approaching its patent horizon. That's not just a label expansion — it's a clock-management strategy. Plenty to track this week.

That's your Pharma Closeout for Monday. Servier's two-point-six-five billion dollar muscular dystrophy bet, Lilly stacking deals from GLP-2 to vaccines to in vivo CAR-T, Skyhawk stabilizing Huntington's patients against natural history decline, ASCO rewriting the oncology playbook, Xocova as the first oral COVID prophylaxis, and the White House redrawing the childhood vaccine map. This industry packed a full week into one Monday, and honestly, we love it. If this briefing keeps you sharp, follow us on Spotify and drop a rating — it helps others in the industry find the show. We're back tomorrow.

Enjoy your Monday evening, everyone. See you tomorrow. ### Episode Metadata **Title:** Servier's $2.65B Edgewise Muscular Dystrophy Deal; FDA Approves First Oral COVID Prophylaxis; Childhood Vaccine Schedule Overhaul | Jun 01, 2026 **Description:** Servier pays $1.55B upfront for Edgewise's sevasemten in a muscular dystrophy deal worth up to $2.65B. FDA approves Shionogi's Xocova as the first oral COVID prophylaxis, Trump overhauls the childhood vaccine schedule, Lilly licenses Hanmi's GLP-2 drug, and ASCO data reshapes competitive dynamics in lung, pancreatic, and prostate cancer. **Tags:** Servier, Edgewise Therapeutics, sevasemten, muscular dystrophy, Becker, Duchenne, Xocova, ensitrelvir, Shionogi, COVID-19, childhood vaccines, Eli Lilly, Hanmi, sonefpeglutide, GLP-2, short bowel syndrome, ASCO 2026, ivonescimab, Revolution Medicines, Skyhawk Therapeutics, SKY-0515, Huntington's disease, Merck, Pfizer, Kelonia, CAR-T, Priority Review Voucher, Replimune, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #